A team at RIKEN in Japan sequenced the immune cells of seven people who had lived past 110 in 2019 and found something that shouldn’t, by the textbook, exist in such numbers. Scattered through their blood were CD4 T cells — the “helper” cells whose job is normally to direct the immune response, not to kill anything directly — that had somehow acquired the killing machinery of their cousins, the CD8 cytotoxic T cells. In most healthy adults, these CD4 cytotoxic T lymphocytes, or CD4 CTLs, make up a few percent of the T cell population at most. In the supercentenarians, they averaged a quarter of all T cells present, with the most dominant clones alone accounting for 15 to 35 percent of the entire CD4 pool. The cells weren’t just numerous; they behaved like killers, producing the same inflammatory signalling molecules, interferon-gamma and TNF-alpha, on stimulation as classic cytotoxic T cells, and running a transcriptional program almost indistinguishable from that of CD8 CTLs, despite still carrying the CD4 marker that supposedly disqualified them from that role.

This week, the same Osaka University group, led by Kousuke Hashimoto, published a follow-up in Cell Reports that fills in the timeline and raises the stakes. Working with blood from twenty-eight Japanese adults split into three brackets — ages 70 to 99, centenarians, and supercentenarians — they tracked the CD4 CTL fraction rising steadily with age: a median of 4 percent in the youngest group, 9.6 percent in centenarians, and 17.6 percent in those past 110. The expansion, they found, is not a gradual thinning of the whole population toward cytotoxicity but the explosive growth of a handful of clones: the single largest clone in each person’s CD4 CTL pool accounted for an average of 33.3 percent of it, and in one centenarian, more than half. Crucially, these clones showed no sign of exhaustion, the state in which T cells that have been fighting the same target for too long lose their potency. Instead they remained active, cycling, and — when the researchers matched the receptor sequences of the dominant clones against a public database of cancer-associated T cell repertoires — turned up nearly three dozen matches to T cells previously found infiltrating lung, breast, and liver tumours. None of the study’s centenarians or supercentenarians had been diagnosed with those cancers, which led Hashimoto to a striking, if necessarily speculative, interpretation: that these expanded clones may be quietly recognising and suppressing malignant or abnormal cells before they ever progress to detectable disease.

It is worth being precise about what has and hasn’t been shown. The paper is explicit that it does not establish that CD4 CTLs cause longevity, or that their abundance is protective against cancer; the correlation between age and cell count is real, but the causal arrow is unproven, and the sample — twenty-eight people, all Japanese — is small enough that generalising to other populations is premature. The pattern is also not exclusive to the very old: one participant younger than 100 had a higher proportion of these cells than anyone else in the study, a reminder that whatever is driving this expansion is not simply a clock running out. Independent researchers have been similarly measured. Alon Monsonego, who studies CD4 CTLs at Ben-Gurion University and was not involved in either paper, has described the new work as useful rather than a breakthrough — a foundation for follow-up studies rather than a finished explanation.

Still, the finding sits awkwardly against a default assumption in immunology, sometimes called immunosenescence: that the immune system simply wears down with age, its cells growing fewer, less responsive, and less able to distinguish threat from self. What the two Osaka studies suggest instead is a system that, at its very extreme, is still doing something — reorganising, redeploying, converting general-purpose helper cells into what looks like a standing army of specialists tuned to whatever chronic, low-grade threats a body accumulates across eleven decades of life. Hashimoto’s own framing captures this: “immune aging is not simply a process of decline.” Whether that reorganisation is a cause of exceptional longevity, a downstream consequence of it, or simply a marker that travels alongside it, remains to be worked out. But the fact that a healthy immune system might still be actively adapting at 110 — rather than merely failing more slowly than everyone else’s — is itself worth sitting with. DE